An investigation on behalf of investors in KemPharm Inc (NASDAQ:KMPH) shares over potential wrongdoing at KemPharm Inc was announced and NASDAQ:KMPH stockholders should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 11/02/2016 -- An investigation on behalf of investors in shares of KemPharm Inc (NASDAQ:KMPH) was announced over potential breaches of fiduciary duties by certain officers and directors at KemPharm Inc.
Investors who purchased shares of KemPharm Inc (NASDAQ:KMPH) and currently hold any of those NASDAQ:KMPH shares have certain options and should contact the Shareholders Foundation at email@example.com or call 858-779-1554.
The investigation by a law firm concerns whether certain KemPharm directors breached their fiduciary duties and caused damage to the company and its shareholders.
KemPharm Inc conducted its initial public offering in April 2015. Shares of KemPharm Inc (NASDAQ:KMPH) reached as high as $23.63 per share in September 2015.
On May 5, 2016, KemPharm Inc announced that the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee of the FDA had reviewed and voted on Apadaz, determining by a vote of 16 to 4 that Apadaz should be approved for its proposed indication of the management of acute pain that requires an opioid, but voted 18 to 2 against inclusion of abuse deterrent labeling for the product.
Shares of KemPharm Inc (NASDAQ:KMPH) declined from $18.53 per share in late April 2016 to as low as $3.69 per share in July 2016.
On October 11, 2016, NASDAQ:KMPH shares closed at $4.79 per share.
Those who purchased shares of KemPharm Inc have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego